Surrey Heartlands

Joint Formulary & PAD

Levomepromazine - Schizophrenia

You are here : Home > Formulary Search > Levomepromazine - Schizophrenia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD2
Restrictions / Comments :
Important

This drug (for this indication) has not been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an application to APC.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Levomepromazine
Indication :
Schizophrenia
Group Name :
Keywords :
Brand Names Include :
Levorol
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Levomepromazine is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Schizophrenia.

Committee Recommendations (1)

25 Jun 24 - Not Set

Levomepromazine tablets 6.25mg

This drug has not yet been assessed for formulary status [for this indication] and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.